Statistics from Altmetric.com
Relapsing polychondritis (RPC) is an uncommon but often life-threatening multisystem disease characterised by recurrent or persistent inflammation of cartilaginous tissues, with no known consistently efficacious treatment.1 A T cell-predominant autoimmune aetiology has been implicated.2 Abatacept is a costimulation modulator that suppresses T cell activity, and one report has suggested that abatacept may be efficacious in one case, but did not present disease endpoints.3 We report here our experience with abatacept in four subjects with RPC, which was performed in the context of a small open-label study (NCT01272856).
Key clinical characteristics of the subjects, all meeting the Michet criteria for RPC,4 are shown in table 1. Written informed consent was obtained from all subjects. Abatacept 125 mg subcutaneously weekly was planned to be administered for 24 weeks, but two subjects discontinued early: subject 001 developed worsening pulmonary and neurological disease and discontinued at …
Contributors SLP, DR: conception and design, acquisition of data or analysis and interpretation of data. SLP: drafting the article or revising it critically for important intellectual content. SLP, DR: final approval of the version published.
Funding This work was supported in part by a grant from Bristol-Meyers Squibb to the Benaroya Research Institute.
Competing interests This study was supported in part by a grant from Bristol-Meyers Squibb, the manufacturer of abatacept, to the Benaroya Research Institute.
Ethics approval Benaroya Research Institute.
ClinicalTrials.gov identifier NCT01272856
Provenance and peer review Not commissioned; internally peer reviewed.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.